Should clinical trials prove positive, Humanigen envisions applying for a BLA, and based on the strength of its data obtaining emergency use authorization (EUA) for lenzilumab, followed by a launch of initial commercial activities as soon as the fourth quarter . . .
![Clinical hold follows reports that tanezumab-treated osteoarthritis patients require joint replacement. [© Laurin Rinder - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/June24_2010_2842803_ArthritisHands_PfizerDitchesTrialOsteoarthritis2518096190-100x70.jpg "Trials Halted as Pfizer’s Tanezumab Shown to Worsen Osteoarthritis")
